BullishAgent BullishAgent Filings Economic Earnings Ratings IPOs Insiders Institutional ETFs Funds Screener
Sign in Register

AZN

AstraZeneca PLC NYSE Listed May 12, 1993
Healthcare ·Drug Manufacturers - General ·GB · astrazeneca.com
$182.58
Mkt Cap $283.1B
52w Low $132.32 62.5% of range 52w High $212.71
50d MA $194.71 200d MA $177.96
P/E (TTM) 14.0x
EV/EBITDA 8.1x
P/B 2.9x
Debt/Equity 0.6x
ROE
P/FCF 11.6x
RSI (14)
ATR (14)
Beta 0.28
50d MA $194.71
200d MA $177.96
Avg Volume 2.2M
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
SIC Code
2834
CIK (SEC)
Phone
44 20 3749 5000
1 Francis Crick Avenue · Cambridge CB2 0AA · GB
Data updated apr 24, 2026 8:19pm · Source: massive.com